drugset

drugset / Trial / NCT05682560

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

NCT05682560 ↗

Phase 2 Completed 30 enrolled StemCyte, Inc. StemCyte Taiwan Co., Ltd. · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.

Timeline

Start: 2023-05-04
Primary completion: 2024-07-26
Completion: 2025-02-27

Publications

Huang YW, Chen YC, Lun Lau EY, Su YC, Tai LK, Rosenthal J, Wang J, Lee TY. REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial. EClinicalMedicine. 2026 Jan 9;91:103737. doi: 10.1016/j.eclinm.2025.103737. eCollection 2026 Jan.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	REGENECYTE	Cell therapy	1e+07 cells/kg	Intravenous

Indications